Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) - Research analysts at William Blair boosted their Q3 2025 earnings estimates for Krystal Biotech in a research report issued to clients and investors on Wednesday, April 2nd. William Blair analyst S. Corwin now anticipates that the company will earn $1.84 per share for the quarter, up from their previous estimate of $1.82. The consensus estimate for Krystal Biotech's current full-year earnings is $6.14 per share. William Blair also issued estimates for Krystal Biotech's Q3 2025 earnings at $1.84 EPS, Q3 2026 earnings at $2.57 EPS, Q3 2026 earnings at $2.57 EPS, Q4 2026 earnings at $2.92 EPS and Q4 2026 earnings at $2.92 EPS.
Several other equities research analysts also recently weighed in on KRYS. Citigroup upped their price objective on shares of Krystal Biotech from $206.00 to $215.00 and gave the stock a "neutral" rating in a report on Thursday, February 20th. Jefferies Financial Group began coverage on Krystal Biotech in a report on Wednesday, March 5th. They set a "buy" rating and a $245.00 target price on the stock. HC Wainwright restated a "buy" rating and issued a $221.00 target price on shares of Krystal Biotech in a research report on Friday, February 28th. Chardan Capital lifted their price target on Krystal Biotech from $212.00 to $218.00 and gave the company a "buy" rating in a research report on Thursday, February 20th. Finally, Cantor Fitzgerald reiterated an "overweight" rating and issued a $215.00 target price on shares of Krystal Biotech in a report on Thursday, February 20th. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Buy" and an average price target of $220.00.
View Our Latest Analysis on KRYS
Krystal Biotech Stock Up 4.0 %
Krystal Biotech stock traded up $6.41 during mid-day trading on Friday, hitting $165.10. 180,294 shares of the company's stock traded hands, compared to its average volume of 292,920. Krystal Biotech has a one year low of $141.72 and a one year high of $219.34. The company has a market cap of $4.76 billion, a PE ratio of 55.10 and a beta of 0.75. The firm has a 50 day moving average price of $173.44 and a 200 day moving average price of $172.60.
Krystal Biotech (NASDAQ:KRYS - Get Free Report) last announced its quarterly earnings results on Monday, February 24th. The company reported $1.52 EPS for the quarter, beating the consensus estimate of $1.29 by $0.23. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The company had revenue of $91.10 million for the quarter, compared to analyst estimates of $91.35 million. During the same quarter last year, the business earned $0.30 earnings per share. Krystal Biotech's revenue was up 116.4% compared to the same quarter last year.
Hedge Funds Weigh In On Krystal Biotech
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Wilmington Savings Fund Society FSB bought a new stake in Krystal Biotech in the third quarter worth approximately $40,000. GF Fund Management CO. LTD. bought a new position in Krystal Biotech during the fourth quarter valued at about $95,000. Covestor Ltd boosted its stake in shares of Krystal Biotech by 972.7% during the 4th quarter. Covestor Ltd now owns 708 shares of the company's stock worth $111,000 after acquiring an additional 642 shares in the last quarter. Avanza Fonder AB acquired a new position in shares of Krystal Biotech during the 4th quarter valued at about $119,000. Finally, KBC Group NV lifted its holdings in Krystal Biotech by 46.3% in the 4th quarter. KBC Group NV now owns 939 shares of the company's stock worth $147,000 after purchasing an additional 297 shares during the last quarter. Institutional investors own 86.29% of the company's stock.
Insider Activity at Krystal Biotech
In other news, insider Suma Krishnan sold 25,000 shares of the business's stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $177.79, for a total transaction of $4,444,750.00. Following the transaction, the insider now directly owns 1,463,711 shares in the company, valued at $260,233,178.69. The trade was a 1.68 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CAO Kathryn Romano sold 750 shares of Krystal Biotech stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $175.22, for a total value of $131,415.00. Following the sale, the chief accounting officer now directly owns 12,604 shares of the company's stock, valued at approximately $2,208,472.88. The trade was a 5.62 % decrease in their position. The disclosure for this sale can be found here. 14.10% of the stock is owned by insiders.
About Krystal Biotech
(
Get Free Report)
Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).
Further Reading
Before you consider Krystal Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Krystal Biotech wasn't on the list.
While Krystal Biotech currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
